Arvinas Inc.

88.61-5.58-5.92%Vol 306.92K1Y Perf 270.78%
Sep 24th, 2021 16:00 DELAYED
BID88.61 ASK88.72
Open93.15 Previous Close94.19
Pre-Market- After-Market-
 - -  - -%
Target Price
128.64 
Analyst Rating
Strong Buy 1.22
Potential %
45.18 
Finscreener Ranking
★★★★+     55.11
Insiders Trans % 3/6/12 mo.
-100/-100/-89 
Value Ranking
★★★★     57.09
Insiders Value % 3/6/12 mo.
-100/-100/-39 
Growth Ranking
★★★★     61.01
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-30 
Income Ranking
 —    -
Price Range Ratio 52W %
77.64 
Earnings Rating
Strong Buy
Market Cap4.36B 
Earnings Date
4th Nov 2021
Alpha0.08 Standard Deviation0.48
Beta1.98 

Today's Price Range

88.1193.15

52W Range

19.68108.46

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-8.16%
1 Month
4.60%
3 Months
16.27%
6 Months
41.05%
1 Year
270.78%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ARVN88.61-5.5800-5.92
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Financial StrengthValueIndustryS&P 500US Markets
14.50
15.00
0.01
0.01
-2 875.80
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-782.70
-757.30
-306.90
-
RevenueValueIndustryS&P 500US Markets
20.90M
0.40
18.06
-
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.84-1.03-22.62
Q01 2021-0.78-0.84-7.69
Q04 2020-0.78-0.99-26.92
Q03 2020-0.67-0.79-17.91
Q02 2020-0.58-0.65-12.07
Q01 2020-0.59-0.565.08
Q04 2019-0.53-0.56-5.66
Q03 2019-0.310.21167.74
Earnings Per EndEstimateRevision %Trend
9/2021 QR3.90543.18Positive
12/2021 QR-0.7313.10Positive
12/2021 FY1.12132.46Positive
12/2022 FY-2.9627.09Positive
Next Report Date4th Nov 2021
Estimated EPS Next Report3.90
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume306.92K
Shares Outstanding49.20M
Shares Float41.83M
Trades Count5.08K
Dollar Volume17.90M
Avg. Volume463.61K
Avg. Weekly Volume243.96K
Avg. Monthly Volume358.62K
Avg. Quarterly Volume456.58K

Arvinas Inc. (NASDAQ: ARVN) stock closed at 88.61 per share at the end of the most recent trading day (a -5.92% change compared to the prior day closing price) with a volume of 309.97K shares and market capitalization of 4.36B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 133 people. Arvinas Inc. CEO is John Houston.

The one-year performance of Arvinas Inc. stock is 270.78%, while year-to-date (YTD) performance is 4.33%. ARVN stock has a five-year performance of %. Its 52-week range is between 19.68 and 108.46, which gives ARVN stock a 52-week price range ratio of 77.64%

Arvinas Inc. currently has a PE ratio of -26.30, a price-to-book (PB) ratio of 8.71, a price-to-sale (PS) ratio of 232.53, a price to cashflow ratio of 25.60, a PEG ratio of 2.32, a ROA of -36.09%, a ROC of -41.90% and a ROE of -41.91%. The company’s profit margin is -%, its EBITDA margin is -757.30%, and its revenue ttm is $20.90 Million , which makes it $0.40 revenue per share.

Of the last four earnings reports from Arvinas Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $3.90 for the next earnings report. Arvinas Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Arvinas Inc. is Strong Buy (1.22), with a target price of $128.64, which is +45.18% compared to the current price. The earnings rating for Arvinas Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arvinas Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arvinas Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.35, ATR14 : 4.13, CCI20 : -23.35, Chaikin Money Flow : 0.21, MACD : 1.21, Money Flow Index : 62.53, ROC : -3.56, RSI : 45.20, STOCH (14,3) : 23.15, STOCH RSI : 0.00, UO : 44.87, Williams %R : -76.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arvinas Inc. in the last 12-months were: Bradley Margus (Sold 29 940 shares of value $2 545 168 ), Edward Kennedy (Buy at a value of $199 909), Ian Taylor (Option Excercise at a value of $823 296), Ian Taylor (Sold 45 894 shares of value $3 485 300 ), John G. Houston (Option Excercise at a value of $1 538 752), John G. Houston (Sold 98 037 shares of value $8 587 518 ), John Houston (Option Excercise at a value of $728 960), John Houston (Sold 44 000 shares of value $3 466 601 ), Liam Ratcliffe (Buy at a value of $9 999 990), Ronald Peck (Option Excercise at a value of $531 600), Ronald Peck (Sold 21 363 shares of value $1 670 391 ), Sean A. Cassidy (Option Excercise at a value of $733 744), Sean A. Cassidy (Sold 44 180 shares of value $3 464 123 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (88.89 %)
7 (77.78 %)
8 (88.89 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (11.11 %)
2 (22.22 %)
1 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.22
Strong Buy
1.44
Strong Buy
1.22

Arvinas Inc.

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.

CEO: John Houston

Telephone: +1 203 535-1456

Address: 395 Winchester Avenue, New Haven 06511, CT, US

Number of employees: 133

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

56%44%

Bearish Bullish

48%52%

News

Stocktwits